Login to Your Account



Biomarin sees strong response to Batten disease therapy

By Michael Fitzhugh
Staff Writer

Thursday, March 3, 2016

Positive data from a phase I/II trial of Biomarin Pharmaceutical Inc.'s experimental therapy for CLN2, a type of the lysosomal storage disorder Batten disease, has the company cruising toward midyear regulatory filings with an eye to gaining approvals for the drug during the first half of 2017.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription